{"schema_version":"secwatch.filing_event.v1","accession":"0001773751-23-000027","form_type":"8-K","ticker":"HIMS","cik":"0001773751","company_name":"Hims & Hers Health, Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.490601+00:00","generated_at":"2026-06-18T23:52:14.641437+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Hims & Hers Q4 revenue $167.2M (+97% YoY); achieves first positive adjusted EBITDA of $3.9M","bullets":["Q4 revenue $167.2M, up 97% YoY; full year revenue $526.9M, up 94% YoY.","Q4 net loss narrowed to $10.9M from $31.2M; adjusted EBITDA positive $3.9M (vs -$7.1M).","Subscribers surpassed 1M (1.04M), up 88% YoY; monthly online revenue per subscriber $55.","FY2023 guidance: revenue $735-755M, adjusted EBITDA $20-30M.","Introduced 2025 targets: at least $1.2B revenue and $100M adjusted EBITDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001773751-23-000027","json":"https://secwatch.observer/filing/0001773751-23-000027.json","markdown":"https://secwatch.observer/filing/0001773751-23-000027.md","text":"https://secwatch.observer/filing/0001773751-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1773751/000177375123000027/0001773751-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1773751/000177375123000027/hims-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:52:14.641437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84da26fb9a8c103dcfd23b1ca144a782d1e64080","claim":"Hims & Hers Health, Inc. reported Full Year 2022 results: net income $(65.7) million.","evidence_excerpt":"Full year 2022 revenue of $526.9 million, up 94% year-over-year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1773751/000177375123000027/0001773751-23-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Net income","value":"$(65.7) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"84da26fb9a8c103dcfd23b1ca144a782d1e64080","claim":"Hims & Hers Health, Inc. reported Full Year 2022 results: net income $(65.7) million.","evidence_excerpt":"Net loss was $(65.7) million for the year ended December 31, 2022 compared to $(107.7) million for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1773751/000177375123000027/0001773751-23-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Net income","value":"$(65.7) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ec85ca4a9a146b31780fef5b5ce6b9075ae30c94","claim":"Hims & Hers Health, Inc. reported Q4 2022 results: revenue $167.2 million, net income $(10.9) million.","evidence_excerpt":"Q4 2022 record revenue of $167.2 million, up 97% year-over-year Q4 2022 net loss of $10.9 million and achieves Adjusted EBITDA profitability of $3.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1773751/000177375123000027/0001773751-23-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2022"},{"label":"Revenue","value":"$167.2 million"},{"label":"Net income","value":"$(10.9) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f6c58fbcbe7f49f93dae77bb6946977303b6b381","claim":"Hims & Hers Health, Inc. reported Full Year 2023 results: revenue $735 million to $755 million. Guidance initiated.","evidence_excerpt":"Provides Q1 and full year 2023 guidance, with full year 2023 revenue in the range of $735 million to $755 million and Adjusted EBITDA in the range of $20 million to $30 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1773751/000177375123000027/0001773751-23-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$735 million to $755 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}